I disagree.
FDA approval is a long and windy road that most pharma plays don't ever get. However, BOT has. That is a huge issue with taking drugs to market.
Now, phase 2 results are wrapping up.
Without saying the curse word too many times, a T/O is very common for bio plays that have validated their product in humans and can highlight the mechanism of action. Why? Big pharma plays will swallow any start-up with these checks. The money to be made for them and the resources they can chuck at a product that works is exponential.
I don't think all are holding BOT hoping for it to reach market, but rather a buy-out based on positive phase 2 results.
Lest we forget, there are multiple products here ....
These are just my thoughts.
- Forums
- ASX - By Stock
- BOT
- Bot Chart
Bot Chart, page-995
-
- There are more pages in this discussion • 13,169 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
34.5¢ |
Change
0.015(4.55%) |
Mkt cap ! $624.4M |
Open | High | Low | Value | Volume |
32.5¢ | 35.0¢ | 32.3¢ | $2.184M | 6.494M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 38963 | 34.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
34.5¢ | 34769 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 38963 | 0.340 |
3 | 131100 | 0.335 |
8 | 216172 | 0.330 |
3 | 261000 | 0.325 |
10 | 437414 | 0.320 |
Price($) | Vol. | No. |
---|---|---|
0.345 | 34769 | 1 |
0.350 | 178814 | 5 |
0.355 | 21000 | 2 |
0.360 | 93520 | 6 |
0.365 | 201920 | 5 |
Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |